Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $106 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $106.
June 12, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh has reiterated a Buy rating on Axsome Therapeutics and maintained a price target of $106.
The reiteration of a Buy rating and the maintenance of a $106 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100